老年小细胞肺癌的治疗进展

Advances in Treatments for Small Cell Lung Cancer in Elderly Patients

小细胞肺癌在每年新发肺癌中约占20%,其中约30%患者年龄超过70岁,10%患者年龄超过80岁。化疗是小细胞肺癌治疗的基石,但是老年患者由于年龄相关的一些疾病导致化疗耐受性差,因此疗效相对年轻患者差。解决办法就是根据老年患者特点(老年状态评分系统)设计对应的临床试验。本研究对老年小细胞肺癌治疗的现状进行综述。

Small cell lung cancer （SCLC） accounts for approximately 20% of lung carcinomas. Nearly 30% of patients with lung cancer are diag- nosed over the age of 70 years and about 10% over 80 years. Chemotherapy is the cornerstone of treatment for SCLC. However, elderly patients tol- erate chemotherapy poorly as compared to their younger counterparts because of age-related progressive reduction in organ functions and the pres- ence of eomorbidities. Therefore, the best approach towards the development of active and well-tolerated chemotherapy regimens for elderly patients with SCLC is to design clinical trials that are based specifically on geriatric assessments. This review focuses on the major issues related to the treatment of elderly patients with SCLC.